Home/Pipeline/JNJ-77242113

JNJ-77242113

Psoriasis

Phase 3Active

Key Facts

Indication

Psoriasis

Phase

Phase 3

Status

Active

Company

Johnson & Johnson

About Johnson & Johnson

Johnson & Johnson is a diversified healthcare leader with a mission to prevent, treat, and cure complex diseases through smarter, less invasive, and more personalized solutions. Its strategic pivot to a pure-play Innovative Medicine and MedTech structure enhances focus and capital allocation towards high-margin, innovative therapies and advanced technologies. The company sustains its leadership through a formidable R&D engine, a robust commercial portfolio featuring multiple blockbuster drugs, and a disciplined strategy of strategic business development and portfolio optimization.

View full company profile

Therapeutic Areas

Oncology Immunology Neuroscience Cardiopulmonary Cardiovascular Orthopaedics Surgery Vision

Other Psoriasis Drugs

Drug	Company	Phase	Status
CYPS317	FibroBiologics	Discovery	Active
PEP Biologic™	Intent Biologics	Unknown	Active
DMT410	Dermata Therapeutics	Preclinical	Exploratory
IL23R program	Acellera	Pre-clinical	Hit-to-Lead
Undisclosed Psoriasis Program	Nepsone	Preclinical	Active
TEM-1657 (Topical)	Temisis	Pre-clinical	Active
TEM-1657 (Oral)	Temisis	Pre-clinical	Active
AIM Platform	Phaim Pharma	Pre-clinical	Active
orismilast	UNION therapeutics	Phase 2	Active
CT-P55	Celltrion	Phase 3	Active
IL-17A/F Inhibitor (CSPC-2232)	CSPC Pharmaceutical Group Limited	Phase III	Active
Zasocitinib (TAK-279)	Takeda Pharmaceutical	Phase 3	Active